Evidence map›Paper›PMID 42367769›Full record

ArticleFrontiers in immunology2026

HLA-G expression in non-small cell lung cancer: prognostic significance and interplay with PD-L1 and CD8

Giulia Querzoli, Giuseppe Bogina, Marcella Marconi, Nicola Tumino, Paola Vacca, Luisella Righi, Sara Pilotto, Anna Caliò, Luca Cima, Stefano Gobbo and 10 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Giulia Querzoli *Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Giuseppe Bogina *Pathology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, VR, Italy.
Marcella MarconiPathology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, VR, Italy.
Nicola TuminoInnate Lymphoid Cells Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paola VaccaInnate Lymphoid Cells Unit, Immunology Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Luisella RighiPathology Unit, Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Italy.
Sara PilottoDepartment of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Anna CaliòDepartment of Diagnostic and Public Health, Section of Pathology, University of Verona and Verona University Hospital Trust, Verona, Italy.
Luca CimaPathology Unit, Verona University Hospital Trust, Verona, Italy.
Stefano GobboDepartment of Diagnostic and Public Health, Section of Pathology, University of Verona and Verona University Hospital Trust, Verona, Italy.
Matthew J CecchiniDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Gaetano PaolinoPathology Unit, ASST Spedali Civili di Brescia, Brescia, Italy.
Francesco CiompiDepartment of Pathology, Radboud University Medical Center, Nijmegen, Netherlands.
Roberto S AccollaLaboratories of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, Varese, Italy.
Aldo ScarpaDepartment of Diagnostic and Public Health, Section of Pathology, University of Verona and Verona University Hospital Trust, Verona, Italy.
Gianluigi LunardiLaboratory Medicine, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, VR, Italy.
Emanuela MarcenaroDepartment of Experimental Medicine, University of Genova, Genova, Italy.
Lorenzo MorettaTumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Giuseppe ZamboniPathology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, VR, Italy.
Enrico MunariPathology Unit, Verona University Hospital Trust, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: HLA-G is a non-classical major histocompatibility complex class I molecule with potent immunosuppressive activity and is increasingly recognized as an immune-checkpoint axis in cancer. Its prognostic significance in non-small cell lung cancer (NSCLC), particularly in relation to PD-L1 expression and CD8 Methods: We retrospectively analyzed 314 surgically resected NSCLCs assembled in tissue microarrays and stained for HLA-G, PD-L1, and CD8. HLA-G and PD-L1 were scored as positive when ≥1% of tumor cells showed membranous staining, whereas CD8 Results: HLA-G was expressed in 50 of 314 tumors (16%), PD-L1 in 106 of 314 (33.8%), and high CD8 density in 160 of 314 (51%). In HLA-G-negative tumors, high CD8 Discussion: In combined biomarker analyses, the favorable prognostic effect of CD8

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesHLA-G AntigensLung NeoplasmsLymphocytes, Tumor-InfiltratingAdultAgedBiomarkers, TumorFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisRetrospective StudiesB7-H1 AntigenBiomarkers, TumorCD274 protein, humanHLA-G AntigensHLA-Gimmune evasionnon-small cell lung cancerPD-L1tumor-infiltrating lymphocytes

Identifiers

PMID42367769
PMCPMC13303491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.